{"filing":{"accession_number":"0001193125-26-248326","cik":"0001370053","ticker":"ANAB","company_name":"ANAPTYSBIO, INC","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"anab-20260529.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526248326/anab-20260529.htm"},"events":[{"id":8124,"run_id":7131,"accession_number":"0001193125-26-248326","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The filing discloses a spin-off and separation of First Tracks Biotherapeutics, Inc. from AnaptysBio, with distribution of First Tracks common stock to stockholders. While the Item 7.01 disclosure itself is limited to tax guidance (Form 8937), the underlying transaction—a material corporate separation and dividend distribution—is a significant capital structure event that would materially affect investor assessment. This does not fit neatly into ma_activity (which typically covers acquisitions/mergers rather than spin-offs), so other_material is most appropriate.","company_name":"ANAPTYSBIO, INC","ticker":"ANAB","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2720,"accession_number":"0001193125-26-248326","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a spin-off and separation of First Tracks Biotherapeutics, Inc. from AnaptysBio, with distribution of First Tracks common stock to stockholders. While the Item 7.01 disclosure itself is limited to tax guidance (Form 8937), the underlying transaction—a material corporate separation and dividend distribution—is a significant capital structure event that would materially affect investor assessment. This does not fit neatly into ma_activity (which typically covers acquisitions/mergers rather than spin-offs), so other_material is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:58.130598+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2720,"accession_number":"0001193125-26-248326","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a spin-off and separation of First Tracks Biotherapeutics, Inc. from AnaptysBio, with distribution of First Tracks common stock to stockholders. While the Item 7.01 disclosure itself is limited to tax guidance (Form 8937), the underlying transaction—a material corporate separation and dividend distribution—is a significant capital structure event that would materially affect investor assessment. This does not fit neatly into ma_activity (which typically covers acquisitions/mergers rather than spin-offs), so other_material is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:58.130598+00:00","company_name":"ANAPTYSBIO, INC","ticker":"ANAB","filing_date":"2026-05-29"}]}